Trial reportEye (London, England)2015
Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Trial report in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Cataract surgery in diabetes mellitus: A systematic review.Indian journal of ophthalmology · 2018Pooled it
- Impact of baseline visual acuity, time-in-range and early treatment on functional outcomes in DMO: insights from the IRISS outcomes.Eye (London, England) · 2026Article
- What have we learned from a decade treating patients with diabetic macular oedema with 0.19 mg fluocinolone acetonide intravitreal implant?Eye (London, England) · 2025Review
- Intravitreal therapy for the management of diabetic retinopathy: A concise review.World journal of experimental medicine · 2024Review
- Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients.Eye (London, England) · 2024Article
- Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study.The British journal of ophthalmology · 2023Article
- Pathogenesis and current therapies for non-infectious uveitis.Clinical and experimental medicine · 2023Review
- Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular oedema evaluated as the area-under-the-curve.Eye (London, England) · 2023Article
- Diabetic Macular Oedema Guidelines: An Australian Perspective.Journal of ophthalmology · 2023Review
- Intravitreal Fluocinolone Acetonide Implant (ILUVIENDrug design, development and therapy · 2023Review
- Optimizing treatment for diabetic macular edema during cataract surgery.Frontiers in endocrinology · 2023Review
- Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries.Ophthalmology and therapy · 2022Article
- An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.Eye (London, England) · 2022Review
- Intravitreal Therapy for Diabetic Macular Edema: An Update.Journal of ophthalmology · 2021Review
- Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.Eye (London, England) · 2020Review
- Comment on "Effectiveness of 190 µg Fluocinolone Acetonide versus 700 µg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis" [Response to Letter].Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIENClinical ophthalmology (Auckland, N.Z.) · 2020Review
- The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.Ophthalmic research · 2020Article
- Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases.Biomedical microdevices · 2019Review
- Cataract in diabetes mellitus.World journal of diabetes · 2019Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
12 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiabetic macular oedema (DMO) is a leading cause of blindness in working-age adults. Slow-release, nonbioerodible fluocinolone acetonide (FAc) implants have shown efficacy in the treatment of DMO; however, the National Institute for Health and Care Excellence recommends that FAc should be used in patients with chronic DMO considered insufficiently responsive to other available therapies only if the eye to be treated is pseudophakic. The goal of this analysis was to examine treatment outcomes in phakic patients who received 0.2 μg/day FAc implant.
methodsThis analysis of the phase 3 FAME (Fluocinolone Acetonide in Diabetic Macular Edema) data examines the safety and efficacy of FAc implants in patients who underwent cataract extraction before (cataract before implant (CBI) group) or after (cataract after implant (CAI) group) receiving the implant. The data were further examined by DMO duration.
resultsBest corrected visual acuity (BCVA) after 36 months was comparable in the CAI and CBI groups. Both the percentage of patients gaining ≥ 3 lines of vision and mean change in BCVA letter score were numerically greater in the CAI group. In addition, most patients who underwent cataract surgery experienced a net gain in BCVA from presurgery baseline as well as from original study baseline.
conclusionsThese data support the use of 0.2 μg/day FAc implants in phakic as well as in pseudophakic patients. These findings will serve as a pilot for design of future studies to evaluate the potential protective effect of FAc implants before cataract surgery in patients with DMO and cataract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.